The repurchase of the Le Meridien vaccine shows management's...

The repurchase of the Le Meridien vaccine shows management's confidence in future developments. The pharmaceutical industry will usher in a new boom cycle. As a full-chain vaccine group, the value of the Le Meridien vaccine is showing. Major products, such as the 13-valent pneumonia vaccine, will help open up more room for imagination in their performance. The deep R&D heritage and product upgrades of the Le Meridien vaccine, plus management buybacks and the progress of new varieties, indicate that its stock price has room for a sharp rise.